Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo

Arthritis and Rheumatism

Volumn 60, Issue 7, 2009, Pages 1998-2007

  Buttgereit, Frank ^a,b   Zhou, Hong ^a,f   Kalak, Robert ^a   Gaber, Timo ^b,c   Spies, Cornelia M ^a,b   Huscher, Dörte ^d   Straub, Ranier H ^e   Modzelewski, James ^a   Dunstan, Colin R ^a   Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Berlin Brandenburg Center for Regenerative Therapies   (Germany)

^d German Rheumatism Research Centre   (Germany)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^f ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; COLLAGEN TYPE 1; CORTICOSTERONE; CORTICOTROPIN; CYTOKINE; GLUCOCORTICOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; BONE TURNOVER; CONTROLLED STUDY; CYTOKINE RELEASE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PRIORITY JOURNAL; PROMOTER REGION; SERUM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ARTHRITIS; AUTOIMMUNE DISEASES; BODY WEIGHT; BONE AND BONES; CORTICOSTERONE; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; JOINTS; MALE; MICE; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOCYTES; SIGNAL TRANSDUCTION;

EID: 67650079427     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24619     Document Type: Article

References (31)

1. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on mechanisms of action [review]. Arthritis Rheum 2004;50:3408-17.
2. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005;353:1711-23.
3. Buttgereit F, Saag K, Cutolo M, da Silva JA, Bijlsma JW. The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis. Scand J Rheumatol 2005;34:14-21.
4. Buttgereit F, Seibel MJ, Bijlsma JW. Glucocorticoids. In: Rich RR, Fleisher TA, Shearer WT, Schroeder H, Frew AJ, Weyland CM, editors. Clinical immunology: principles and practice. 3rd ed. London: Mosby Elsevier; 2008. p. 1293-305.
5. Lowenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 2006;7:1023-9.
6. Bartholome B, Spies CM, Gaber T, Schuchmann S, Berki T, Kunkel D, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004;18:70-80.
7. Buttgereit F, Zhou H, Seibel MJ. Arthritis and endogenous glucocorticoids: the emerging role of the 11β-HSD enzymes. Ann Rheum Dis 2008;67:1201-3.
8. Zhou H, Mak W, Zheng Y, Dunstan CR, Seibel MJ. Osteoblasts directly control lineage commitment of mesenchymal progenitor cells through Wnt signaling. J Biol Chem 2008;283;1936-45.
9. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. Curr Drug Targets Inflamm Allergy 2005;4:325-8.
10. Schett G, Middleton S, Bolon B, Stolina M, Brown H, Zhu L, et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005;52:1604-11.
11. Sher LB, Woitge HW, Adams DJ, Gronowicz GA, Krozowski Z, Harrison JR, et al. Transgenic expression of 11β-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 2004;145:922-9.
12. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 2006;7:274-83.
13. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A, et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol 2006;24:1279-84.
14. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999;42:498-506.
15. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, Wilson J, et al. Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 2004;110:252-66.
16. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
17. Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005;165:1293-7.
18. Kirwan J, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database of Syst Rev 2007;(1):CD006356.
19. Hardy R, Rabbitt EH, Filer A, Emery P, Hewison M, Stewart PM, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008. E-pub ahead of print.
20. Seckl JR, Walker BR. Minireview: 11β-hydroxysteroid dehydrogenase type 1: a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371-6.
21. Lakshmi V, Monder C. Purification and characterization of the corticosteroid 11 β-dehydrogenase component of the rat liver 11 β-hydroxysteroid dehydrogenase complex. Endocrinology 1988;123:2390-8.
22. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-92.
23. Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006;54:1463-72.
24. Balga R, Wetterwald A, Portenier J, Dolder S, Mueller C, Hofstetter W. Tumor necrosis factor-α: alternative role as an inhibitor of osteoclast formation in vitro. Bone 2006;39:325-35.
25. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001;40:623-30.
26. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
27. Straub RH, Dhabhar FS, Bijlsma JW, Cutolo M. How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis [review]. Arthritis Rheum 2005;52:16-26.
28. Barber AE, Coyle SM, Marano MA, Fischer E, Calvano SE, Fong Y, et al. Glucocorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J Immunol 1993;150:1999-2006.
29. Dhabhar FS, McEwen BS. Enhancing versus suppressive effects of stress hormones on skin immune function. Proc Natl Acad Sci U S A 1999;96:1059-64.
30. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 2004;1024:124-37.
31. Zhou H, Mak W, Kalak R, Street J, Fong-Yee C, Zheng Y, et al. Glucocorticoid signalling through osteoblasts is essential for cranial skeletal development. Development 2009;136:427-36.